Atopic Dermatitis – Pipeline Review, H2 2019 : ResearchByMarkets.com

Research By Markets adds Market Research Report - Atopic Dermatitis – Pipeline Review, H2 2019 : ResearchByMarkets.com

For detailed information: https://www.researchbymarkets.com/report/atopic-dermatitis-pipeline-review-h2-2019-452492.html

Atopic Dermatitis – Pipeline Review, H2 2019

Summary

Atopic Dermatitis – Pipeline Review, H2 2019, provides an overview of the Atopic Dermatitis (Dermatology) pipeline landscape.

Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.

Report Highlights

Atopic Dermatitis – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atopic Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis (Atopic Eczema) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 12, 47, 25, 3, 57, 22 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 6 and 2 molecules, respectively.

Atopic Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Dermatology).
– The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Atopic Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Atopic Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Dermatology)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Dermatology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned:
Abate Med Inc
AbbVie Inc
Abeome Corp
Aclaris Therapeutics Inc
Afecta Pharmaceuticals Inc
Akaal Pharma Pty Ltd
Allergan Plc
Almirall SA
Amgen Inc
Amorepacific Corp
AOBiome LLC
Apimeds Inc
Arcutis Inc
Arena Pharmaceuticals Inc
Arrien Pharmaceuticals LLC
Asana BioSciences LLC
Aslan Pharmaceuticals Ltd
Astellas Pharma Inc
AstraZeneca Plc
Atrapos Therapeutics LLC
Azitra Inc
Bausch Health Companies Inc
Biomimetix JV LLC
Blueberry Therapeutics Ltd
Boehringer Ingelheim International GmbH
Boston Pharmaceuticals Inc
Botanix Pharmaceuticals Ltd
Calcico Therapeutics Ltd
Celgene Corp
ChironWells GmbH
Chugai Pharmaceutical Co Ltd
Clayton Biotechnologies Inc
Clevexel Pharma SAS
CSA Biotechnologies LLC
Cutanea Life Sciences Inc
Daiichi Sankyo Co Ltd
Dermata Therapeutics LLC
Dermavant Sciences Inc
DermBiont Inc
Devonian Health Group Inc
DongKoo Bio & Pharma Co Ltd
DURECT Corp
EHL Bio Co Ltd
Eli Lilly and Co
Evelo Biosciences Inc
Evotec SE
F. Hoffmann-La Roche Ltd
Fountain Biopharma Inc
Galapagos NV
Galderma SA
General Regeneratives Shanghai Ltd
GI Innovation Co Ltd
GlaxoSmithKline Plc
Helix BioMedix Inc
Hill Dermaceuticals Inc
Hoth Therapeutics Inc
Huons Co Ltd
Ichnos Sciences Inc
Immune Pharmaceuticals Inc
Incyte Corp
Inflamalps SA
Innovation Pharmaceuticals Inc
Innovimmune Biotherapeutics Inc
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
JiangSu Qyuns Therapeutics Co Ltd
JW Pharmaceutical Corp
Kang Stem Biotech Co Ltd
Kine Sciences
Kiniksa Pharmaceuticals Corp
KoBioLabs Inc
Krystal Biotech Inc
Kv1.3 Therapeutics
Kymab Ltd
Kyowa Kirin Co Ltd
Larix Bioscience LLC
Lead Pharma Holding BV
Lemonex Inc
Leo Pharma AS
Lipid Biologics LLC
Lypanosys Pte Ltd
Madam Therapeutics BV
Matrisys Bioscience Inc
MC2 Therapeutics AS
Medicenna Therapeutics Corp
Micreos BV
Nektar Therapeutics
Nepsone ehf
Neuracle Science Co Ltd
NeuroCycle Therapeutics GmbH
Next Science Ltd
NovaCell Technology Inc
Novan Inc
Novartis AG
Oasis Pharmaceuticals LLC
OliX Pharmaceuticals Inc
Ondek Pty Ltd
Orbis Biosciences Inc
Otsuka Holdings Co Ltd
Pantherics Inc
Pfizer Inc
PHI Therapeutics Inc
Polyrizon Ltd
Portola Pharmaceuticals Inc
Provectus Biopharmaceuticals Inc
Pyramid Biosciences Inc
Qurient Co Ltd
Ralexar Therapeutics Inc
RAPT Therapeutics Inc
Regeneron Pharmaceuticals Inc
Ribomic Inc
SCM lifescience Co Ltd
Seelos Therapeutics Inc
Servatus Ltd
Shaperon Inc
Shulov Innovative Science Ltd
Sienna Biopharmaceuticals Inc
Signum Biosciences Inc
Signum Dermalogix Inc
Sosei Heptares
Spherium Biomed SL
StemRIM Inc
sterna biologicals Gmbh & Co KG
Suzhou Connect Biopharmaceuticals Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
TaiwanJ Pharmaceuticals Co Ltd
Temisis Therapeutics
The Geneva Biotech Center SA
Therabest Co Ltd
Tianjin Hemay Bio-Tech Co Ltd
Tolerys SA
Torrent Pharmaceuticals Ltd
Transdermal Therapeutic Technologies LLC
Union Therapeutics AS
Vasomune Inc
VivaCell Biotechnology Espana SL
Voronoi
vTv Therapeutics Inc
Welichem Biotech Inc
XBiotech Inc
Xencor Inc
Zhejiang I-Biological Technology Co Ltd


For queries regarding this report: https://www.researchbymarkets.com/sample-request/452492

Contact Us:
ResearchByMarkets.com
Sales Desk
enquiry@researchbymarkets.com
https://www.researchbymarkets.com
https://www.researchbymarkets.com/aboutus

Follow us on Social Media:
Facebook: https://www.facebook.com/researchbymarkets/
LinkedIn: https://www.linkedin.com/company/researchmarkets
Twitter: https://twitter.com/ResearchByMrkts

Ritesh Tiwari is the Founder of Research By Markets, a leading Market Research Reports Reseller trusted by Fortune listed companies for their requirements of Syndicated and Custom Market Research Reports. Ritesh has an overall experience of 18+ years in Recruitments, Sales and Operations. He has been associated with the Market Research industry for the past 7 years. He is an avid foodie as well as a huge football fan being a supporter of Manchester United (EPL) and FC Barcelona (La Liga). Get in touch with him via ritesh@researchbymarkets.com. *Market Research News is a part of Research By Markets.